Major Depressive Disorder Clinical Trial
Official title:
A Phase I, Multiple-Dose, Randomized, Double-Blind, Oral Tyramine Pressor Response Study Comparing CX157 Tablets to Placebo in Healthy Male Volunteers
The objectives of this study were to examine the cardiovascular sensitivity to oral tyramine after establishment of steady state with CX157 Modified Release (MR) Tablets, 125 mg administered twice per day (BID) in healthy volunteers compared to placebo; and to investigate the general safety, tolerability and pharmacokinetic profile of CX157 tablets at steady state compared to placebo.
Methodology: The trial was a Phase 1, single center, DB, three-period study of
cardiovascular safety following oral administration of encapsulated tyramine prior to
treatment with double-blind (DB) study drug (CX157 Modified Release Tablets, 125 mg
administered twice per day (BID) or matching placebo administered BID) and the
administration of tyramine in yogurt along with a standard meal during the DB study
treatment administration, after CX157 reached steady state.
Prior to treatment with DB study treatment, baseline cardiovascular sensitivity to oral
tyramine administered in a fasting state was established in 15 subjects during Period 1 Days
1-3. Following completion of Period 1, the study's 12 subjects were randomized to CX157 (10
subjects) or placebo (2 subjects) and treated for six consecutive days (Days 4-9) to reach
steady state. Subjects continued their DB study treatment in Period 3 (Days 10-12); however,
during this period tyramine was administered to subjects in the fed state on Day 10
(tyramine 20 mg), Day 11 (tyramine 40 mg) and Day 12 (tyramine 80 mg).
The tyramine pressor dose (minimum dose of tyramine necessary to achieve endpoint) for
Period 1 was established through a series of three tyramine challenges (24 hours apart) with
tyramine doses based upon a predetermined paradigm. During Period 1, untreated fasting
subjects received an initial tyramine challenge dose of 400 mg and were monitored for SBP
endpoint changes (SBP increase of ≥30 mmHg on three consecutive occasions at least five
minutes apart over a 10-minute (i.e., TYR303). If pressor endpoint was achieved, the
tyramine challenge dose administered on Period 1 Day 2 was reduced to 200 mg. However, if
endpoint was not achieved, the tyramine challenge dose was raised on Period 1 Day 2 to 600
mg. This dose escalation/reduction paradigm was repeated on Period 1 Day 3 based upon the
results of Period 1 Day 2 in order to establish the tyramine pressor dose during that
period.
During Period 2 (Days 4-9) subjects were treated with CX157 or placebo twice daily to reach
the steady state. On Day 8 of Period 2, single-blind yogurt without tyramine was
administered with lunch to familiarize subjects and the clinic staff with the procedures for
Period 3.
The tyramine challenges for Period 3 Days 10 - 12 began after six consecutive days of
treatment with CX157 or placebo twice daily. The tyramine doses for Period 3 were 20, 40,
and 80 mg (24 hours apart). The endpoint for Period 3 was the same as described above for
Period 1, reaching of the pressor endpoint (i.e., TYR303).
The study planned for 12 healthy male volunteer subjects to be randomized at Period 2. Ten
(10) subjects were to be randomized to CX157 MR Tablets, 125 mg and 2 to matching placebo.
Approximately 15 subjects were to enter Period 1 in order to ensure randomization of 12
subjects to Period 2 of the study.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |